News & Updates

Low-intensity shock wave safe, effective on moderate erectile dysfunction
Low-intensity shock wave safe, effective on moderate erectile dysfunction
02 Aug 2022

Men with moderate erectile dysfunction (ED) may benefit from having 12 sessions of low-intensity shock wave therapy (SWT) twice weekly for 6 weeks, with a treatment protocol of 5,000 impulses, 0.0096 mJ/mm2 energy flux density, and 5-Hz frequency, suggests a study.

Low-intensity shock wave safe, effective on moderate erectile dysfunction
02 Aug 2022
Men with multiple sclerosis at risk of erectile dysfunction
Men with multiple sclerosis at risk of erectile dysfunction
01 Aug 2022

Adult men with multiple sclerosis (MS) are more likely to develop erectile dysfunction (ED), indicating that MS is a potential predictor for ED occurrence, suggest the results of a meta-analysis.

Men with multiple sclerosis at risk of erectile dysfunction
01 Aug 2022
Men with untreated hypogonadism at risk of long-term morbidity, death
Men with untreated hypogonadism at risk of long-term morbidity, death
31 Jul 2022

Untreated hypogonadism in men appears to elevate the risk of morbidity in the long term and early mortality based on time-related measures of risk only, according to a study.

Men with untreated hypogonadism at risk of long-term morbidity, death
31 Jul 2022
Which drugs raise risk of urinary tract infections?
Which drugs raise risk of urinary tract infections?
29 Jul 2022 byStephen Padilla

Some medications may directly cause the occurrence of urinary tract infections (UTIs), and a recent study presented at the 37th Annual European Association of Urology Congress (EAU 2022) has identified six drugs that appear to contribute to “significant reporting levels” for infections.

Which drugs raise risk of urinary tract infections?
29 Jul 2022
SOUNDS: Real-world use affirms efficacy, safety of sacral neuromodulator device for OAB
SOUNDS: Real-world use affirms efficacy, safety of sacral neuromodulator device for OAB
28 Jul 2022
Intravesical onabotA instillation safe, but with no clear benefit in urinary incontinence
Intravesical onabotA instillation safe, but with no clear benefit in urinary incontinence
28 Jul 2022 byTristan Manalac

The intravesical instillation of onabotulinumtoxinA (onabotA) for refractory overactive bladder in urinary incontinence is generally safe and well-tolerated, but demonstrates no significant efficacy advantage over placebo, according to a recent study.

Intravesical onabotA instillation safe, but with no clear benefit in urinary incontinence
28 Jul 2022
Short-course quinolones, pivmecillinam on par with standard regimens in uncomplicated cystitis
Short-course quinolones, pivmecillinam on par with standard regimens in uncomplicated cystitis
27 Jul 2022 byJairia Dela Cruz

For women with acute uncomplicated cystitis, treatment regimens that include third- and fourth-generation quinolones and pivmecillinam can be administered in shorter courses, which perform similarly to the currently recommended regimens in terms of achieving symptomatic cure, according to the results of a meta-analysis presented at the 37th Annual European Association of Urology (EAU) Congress.

Short-course quinolones, pivmecillinam on par with standard regimens in uncomplicated cystitis
27 Jul 2022